Health Advance Inc (OTCPK:HADV) signed a letter of intent with Hantian Labs Limited for $1.1 million on September 27, 2016. Health Advance Inc (OTCPK:HADV) entered into a definitive agreement to acquire Hantian Labs Limited on October 13, 2016. Under the terms of the agreement, Health Advance will issue 1.5 shares for every share of Hantian Labs. Health Advance will issue 15 million shares as consideration. Hantian Labs will operate as a subsidiary of Health Advance. On completion, Health Advance will also control 99% of JT Hantian LLC. Christian Diesveld will be appointed as Director of Health Advance. The Company expects to enter into a definitive agreement by October 15, 2016. The deal is subject to due diligence and execution of definitive agreement. The transaction is also subject to shareholders of Hantian Labs, approval for listing on the OTC of consideration shares, execution of securities transfer agreement wherein Rejean Marchildon will acquire the promissory note in the amount of $0.059 million owing to Makmo Trading Corp. from Health Advance and Hantian Labs is required to complete a financing of a minimum of $0.25 million for the marketing of Hantian Labs’ product line. The transaction can be terminated if not closed by January 6, 2017. Health Advance will issue 1.05 million shares to Paul LaMarche as finder’s fee. Health Advance Inc (OTCPK:HADV) completed the acquisition of Hantian Labs Limited on January 16, 2017. Health Advance issued 18 million common shares as a consideration to shareholders of Hantian Labs.